Precigen (NASDAQ:PGEN) Issues Quarterly Earnings Results, Beats Estimates By $0.06 EPS

Precigen (NASDAQ:PGEN) issued its earnings results on Tuesday. The biotechnology company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.01) by $0.06, FiscalAI reports. The business had revenue of $54.98 million during the quarter, compared to analyst estimates of $27.91 million. Precigen had a positive return on equity of 717.50% and a negative net margin of 646.99%.The company’s quarterly revenue was up 6322.7% on a year-over-year basis.

Here are the key takeaways from Precigen’s conference call:

• PAPZIMEOS revenue surged to $53.1 million in Q2 from $21.6 million in Q1, a more than 145% sequential increase that drove Precigen to quarterly net income of $20.1 million, or $0.05 per diluted share.
• Commercial adoption continued to broaden, with more than 500 patients registered through PAPZIMEOS SUPPORT, approximately 315 million covered U.S. lives, and increasing use across major medical centers and community practices. Management said the permanent J-code effective April 1 has helped institutions establish routine reimbursement and treatment workflows.
• Management highlighted a broad FDA label, favorable safety profile, and durability data showing 83% of patients remained in complete response beyond three years as of the April 30 cutoff, with some patients exceeding four years without additional RRP treatment. PAPZIMEOS also received seven-year U.S. market exclusivity through August 2032.
• Precigen expects PAPZIMEOS gross margins to stabilize in the high-80% to low-90% range after remaining pre-launch inventory is sold, while R&D spending is expected to rise as pipeline programs advance. The company said cash, investments, and collection of receivables should fund operations through cash-flow breakeven by the end of 2026.
• The company remains on track to begin a pediatric PAPZIMEOS trial this year, while its EMA marketing application is under review. PRGN-2009 continues in Phase 2 trials with pembrolizumab in HPV-related head and neck and cervical cancers, with updated head-and-neck data expected later in 2026.

Precigen Stock Down 1.2%

NASDAQ:PGEN traded down $0.08 during mid-day trading on Tuesday, hitting $6.53. 7,894,080 shares of the company’s stock traded hands, compared to its average volume of 4,504,153. The company has a fifty day moving average of $5.03 and a 200 day moving average of $4.43. Precigen has a twelve month low of $1.70 and a twelve month high of $6.80. The company has a market capitalization of $2.33 billion, a P/E ratio of -5.53 and a beta of 1.00. The company has a debt-to-equity ratio of 4.62, a quick ratio of 4.12 and a current ratio of 4.82.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PGEN. HC Wainwright reiterated a “buy” rating and issued a $14.00 price target on shares of Precigen in a research note on Monday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precigen in a report on Friday, July 17th. Wall Street Zen cut shares of Precigen from a “buy” rating to a “hold” rating in a report on Sunday, May 31st. Citigroup reiterated an “outperform” rating on shares of Precigen in a research note on Thursday, May 14th. Finally, Citizens Jmp lifted their price objective on Precigen from $9.00 to $11.00 and gave the company a “market outperform” rating in a research report on Thursday, May 14th. Three equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $12.50.

Insider Activity at Precigen

In other Precigen news, insider Donald P. Lehr sold 29,131 shares of the firm’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $4.36, for a total value of $127,011.16. Following the sale, the insider directly owned 755,461 shares of the company’s stock, valued at approximately $3,293,809.96. This trade represents a 3.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Helen Sabzevari sold 346,836 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $5.89, for a total transaction of $2,042,864.04. Following the sale, the chief executive officer directly owned 3,768,872 shares of the company’s stock, valued at $22,198,656.08. The trade was a 8.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 956,500 shares of company stock valued at $5,248,371 over the last 90 days. Company insiders own 41.40% of the company’s stock.

Institutional Trading of Precigen

Several institutional investors have recently made changes to their positions in the company. State Street Corp raised its position in Precigen by 141.1% in the fourth quarter. State Street Corp now owns 10,824,860 shares of the biotechnology company’s stock valued at $45,248,000 after purchasing an additional 6,335,033 shares during the period. Geode Capital Management LLC boosted its stake in shares of Precigen by 15.9% in the fourth quarter. Geode Capital Management LLC now owns 4,462,078 shares of the biotechnology company’s stock valued at $18,653,000 after purchasing an additional 613,340 shares during the period. SymBiosis Capital Partners LLC purchased a new position in Precigen in the 4th quarter valued at approximately $12,540,000. Bank of America Corp DE increased its position in shares of Precigen by 201.1% during the third quarter. Bank of America Corp DE now owns 2,505,992 shares of the biotechnology company’s stock worth $8,245,000 after acquiring an additional 1,673,731 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in shares of Precigen by 196.4% in the fourth quarter. Goldman Sachs Group Inc. now owns 2,173,933 shares of the biotechnology company’s stock valued at $9,087,000 after acquiring an additional 1,440,446 shares in the last quarter. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen News Roundup

Here are the key news stories impacting Precigen this week:

• Positive Sentiment: Revenue and earnings substantially exceeded expectations. Quarterly revenue reached $55.0 million versus analyst estimates of approximately $28 million, while diluted EPS was $0.05 compared with an expected loss of $0.01. Precigen also reported $20.1 million in net income attributable to common shareholders and $22.6 million in operating profit. Precigen Reports Second Quarter 2026 Financial Results
• Positive Sentiment: PAPZIMEOS sales more than doubled sequentially. Net revenue from PAPZIMEOS was $53.1 million, reflecting growing U.S. adoption. Patient-hub enrollment exceeded 500 patients across major medical centers and community practices, suggesting broader commercial reach.
• Positive Sentiment: Management highlighted improving cash-flow prospects and regulatory protection. Precigen said its $38.7 million in cash, cash equivalents and investments, combined with PAPZIMEOS proceeds, is expected to support cash-flow break-even by year-end. The FDA also granted PAPZIMEOS seven years of market exclusivity, strengthening its competitive protection.
• Positive Sentiment: Analyst sentiment remains favorable. HC Wainwright reaffirmed its “buy” rating and $14 price target, while the reported median analyst target is $12.50—well above recent trading levels. Unusual options activity also showed a sharp increase in call buying, indicating elevated bullish speculation.
• Neutral Sentiment: Institutional positioning was mixed. In the latest quarter, 91 institutional investors increased their holdings while 65 reduced positions. Several funds made sizable additions, but Point72, FMR and other investors also cut exposure.
• Negative Sentiment: Insider selling may temper enthusiasm. Company insiders reported no purchases and 22 sales over the past six months. COO Rutul Shah sold 33,772 shares for approximately $219,500 under a pre-arranged Rule 10b5-1 plan; other executives also sold shares. Operating cash flow remained negative at $17.8 million, leaving execution and cash-flow improvement as important risks.

Precigen Company Profile

Precigen, Inc (NASDAQ: PGEN) is a biotechnology company focused on the discovery, development and commercialization of genetic medicines. The company leverages proprietary gene and cell therapy platforms to design targeted therapies for oncology, infectious diseases and rare conditions. Precigen’s approach combines synthetic biology, immuno-oncology and microbiome engineering to create precision treatments intended to enhance efficacy while minimizing off-target effects.

The centerpiece of Precigen’s technology is its OmniCAR platform, which enables the rapid generation of adaptable chimeric antigen receptor (CAR) T-cell products.